BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boudewijns S, Bloemendal M, de Haas N, Westdorp H, Bol KF, Schreibelt G, Aarntzen EHJG, Lesterhuis WJ, Gorris MAJ, Croockewit A, van der Woude LL, van Rossum MM, Welzen M, de Goede A, Hato SV, van der Graaf WTA, Punt CJA, Koornstra RHT, Gerritsen WR, Figdor CG, de Vries IJM. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother 2020;69:477-88. [PMID: 31980913 DOI: 10.1007/s00262-019-02466-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
2 Zhang S, Wang H, Ding X, Xiao Y, Shao Z, You C, Gu Y, Jiang Y. Bidirectional Crosstalk between Therapeutic Cancer Vaccines and the Tumor Microenvironment: Beyond Tumor Antigens. Fundamental Research 2022. [DOI: 10.1016/j.fmre.2022.03.009] [Reference Citation Analysis]
3 Dai X, Wang D, Zhang J. Programmed cell death, redox imbalance, and cancer therapeutics. Apoptosis 2021;26:385-414. [PMID: 34236569 DOI: 10.1007/s10495-021-01682-0] [Reference Citation Analysis]
4 Van Wigcheren GF, De Haas N, Mulder TA, Horrevorts SK, Bloemendal M, Hins-Debree S, Mao Y, Kiessling R, van Herpen CML, Flórez-Grau G, Hato SV, De Vries IJM. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. Oncoimmunology 2021;10:1935557. [PMID: 34239773 DOI: 10.1080/2162402X.2021.1935557] [Reference Citation Analysis]
5 Filin IY, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Recent Advances in Experimental Dendritic Cell Vaccines for Cancer. Front Oncol 2021;11:730824. [PMID: 34631558 DOI: 10.3389/fonc.2021.730824] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Eisendle K, Weinlich G, Ebner S, Forstner M, Reider D, Zelle-Rieser C, Tripp CH, Fritsch P, Stoitzner P, Romani N, Nguyen VA. Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients. J Dtsch Dermatol Ges 2020;18:1270-7. [PMID: 33197129 DOI: 10.1111/ddg.14334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Laustsen A, van der Sluis RM, Gris-Oliver A, Hernández SS, Cemalovic E, Tang HQ, Pedersen LH, Uldbjerg N, Jakobsen MR, Bak RO. Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells. Elife 2021;10:e65528. [PMID: 34473049 DOI: 10.7554/eLife.65528] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, Zamyatnin AA Jr, Ganjalikhani-Hakemi M. mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. Vaccines (Basel) 2021;9:1060. [PMID: 34696168 DOI: 10.3390/vaccines9101060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 2022;11:3. [PMID: 35074008 DOI: 10.1186/s40164-022-00257-2] [Reference Citation Analysis]
10 Lau P, Shen M, Ma F, Chen Y, Zhang J, Su J, Chen X, Liu H. A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma. J Eur Acad Dermatol Venereol 2021. [PMID: 34077578 DOI: 10.1111/jdv.17437] [Reference Citation Analysis]
11 Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy. Mol Cancer 2021;20:69. [PMID: 33858437 DOI: 10.1186/s12943-021-01348-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee EJ, Jang GY, Lee SE, Lee JW, Han HD, Park YM, Kang TH. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. Immunol Lett 2021;240:137-48. [PMID: 34710507 DOI: 10.1016/j.imlet.2021.10.006] [Reference Citation Analysis]
13 Marongiu L, Valache M, Facchini FA, Granucci F. How dendritic cells sense and respond to viral infections. Clin Sci (Lond) 2021;135:2217-42. [PMID: 34623425 DOI: 10.1042/CS20210577] [Reference Citation Analysis]
14 Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022;7:166. [PMID: 35597779 DOI: 10.1038/s41392-022-01007-w] [Reference Citation Analysis]
15 Krekorian M, Cortenbach KRG, Boswinkel M, Kip A, Franssen GM, Veltien A, Scheenen TWJ, Raavé R, van Riessen NK, Srinivas M, de Vries IJM, Figdor CG, Aarntzen EHJG, Heskamp S. In Vivo PET Imaging of Monocytes Labeled with [89Zr]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models. Cancers (Basel) 2021;13:5069. [PMID: 34680219 DOI: 10.3390/cancers13205069] [Reference Citation Analysis]